Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Status:
Recruiting
Trial end date:
2027-05-19
Target enrollment:
Participant gender:
Summary
Complete surgical resection is the standard treatment in early-stage lung cancer. However,
the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung cancers
have high recurrence rate. The efficacy of neoadjuvant treatment by first-generation
EGFR-Tyrosine Kinase Inhibitor(TKI) has been demonstrated, however, that of the
third-generation EGFR-TKI(lazertinib) has not yet been fully investigated. The aim of this
study is to evaluate the efficacy of neoadjuvant Lazertinib in resectable EGFR
mutation-positive NSCLC and clinical application of extracellular vesicles(EVs) based BALF
liquid biopsy to identify EGFR mutation without invasive tissue biopsy.